Table 5.
Univariate and multivariable analyses by logistic regression on factors associated with acute liver injury in patients with SARS‐CoV‐2 infection/COVID‐19
| Parameters | Univariate Analysis | Multivariable Analysis | ||
|---|---|---|---|---|
| OR (95% CI) | P | aOR (95% CI) | P | |
| HBV exposure | ||||
| No HBV | Referent | |||
| Current HBV infection | 1.95 (0.92‐4.11) | 0.081 | 1.93 (0.88‐4.24) | 0.102 |
| Past HBV infection | 2.65 (1.38‐5.10) | 0.003 | 1.25 (0.62‐2.55) | 0.533 |
| Age | 1.05 (1.04‐1.07) | <0.001 | 1.03 (1.01‐1.05) | 0.003 |
| Male gender | 3.27 (1.94‐5.51) | <0.001 | 2.40 (1.40‐4.12) | 0.002 |
| Liver cirrhosis | 1.90 (0.46‐7.88) | 0.377 | ||
| DM | 7.27 (4.53‐11.67) | <0.001 | 2.27 (1.32‐3.91) | 0.003 |
| Use of corticosteroid | 10.22 (6.12‐17.07) | <0.001 | 3.29 (1.83‐5.91) | <0.001 |
| Use of remdesivir | 1.83 (0.96‐3.48) | 0.067 | ||
| Use of interferon‐beta | 4.94 (2.76‐8.84) | <0.001 | ||
| Use of ribavirin | 2.82 (1.79‐4.43) | <0.001 | 2.55 (1.57‐4.14) | <0.001 |
| Use of lopinavir/ritonavir | 4.18 (2.61‐6.70) | <0.001 | 3.20 (1.94‐5.27) | <0.001 |
| Use of antibiotics | 6.95 (3.74‐12.89) | <0.001 | ||
| Use of antifungals | 31.90 (15.73‐64.70) | <0.001 | 5.63 (2.55‐12.45) | <0.001 |
Acute liver injury was defined as ALT and/or AST ≥ 2 × ULN, with total bilirubin ≥2 × ULN and/or international normalized ratio ≥1.7.
P = 0.572 for Hosmer‐Lemeshow goodness‐of‐fit test, which did not indicate a poor fit.